You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
蔚藍生物(603739.SH)子公司擬5.94億元投建動物用生物製品生產基地項目
格隆匯 06-30 15:39

格隆匯 6 月 30日丨蔚藍生物(603739.SH)公佈,為適應行業發展和產業佈局的需要,優化產品結構,公司全資子公司青島蔚藍生物製品有限公司(“生物製品公司”)擬投資建設動物用生物製品生產基地項目,該項目總投資約5.94億元,建築面積為109272.26㎡。項目建設所需資金全部由生物製品公司自行籌集。

該項目總投資金額為約5.94億元,其中,建設投資為5.5435億元,鋪底流動資金為4000.00萬元。項目建設週期為24個月,預計2022年6月投入生產運營。該項目地址位於山東省青島市高新區茂源路北段,佔地面積約79436.80㎡,具體面積以自然資源和規劃部門出讓面積為準。該項目總建築面積約109272.26㎡,主要建設內容包括:生物製品生產車間、動物藥業生產車間、辦公樓、動物實驗樓、公用設施、倉儲中心等。

項目建成後,通過基因工程疫苗、多聯多價疫苗、懸浮培養工藝等研發平台的升級應用,細胞懸浮培養工藝生產線、基因工程疫苗生產線等新型疫苗生產線的驗收、投產,生物製品公司將研製和生產新型的符合市場需求的高質量動物生物製品,滿足畜牧業對疫病預防控制的多樣化需求。

項目的實施將進一步增強公司的研發創新能力,提高公司產品的品質和生產製造水平,豐富公司的產品結構,提升公司的盈利水平,促進公司的可持續發展,符合全體股東的利益和公司長遠發展戰略。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account